VR-VOICES
Behavioral7-10 individual VR assisted therapy for voice-hearing session and two booster sessions, in addition to TAU.
NCT Number: NCT06013748
Rationale: Auditory verbal hallucinations (AVH) - hearing voices that others cannot hear - are common in mental illnesses. For many people AVH are distressing, disabling and persistent, despite medication. Current psychological interventions show low to medium effects. Preliminary studies suggest that an innovative empowering psychological therapy using computer simulations representing the AVH (avatars) can be effective for reducing AVH distress and frequency. Virtual reality (VR) has the potential to improve this treatment. Therefore, we developed a novel VR treatment for this problem. In this study, the effect of this treatment will be investigated.
Objective: To test the effect of a novel VR treatment for AVH (VR-VOICES) on distress and frequency of AVH in patients with a psychiatric disorder. Furthermore, to investigate the effect of VR-VOICES on clinical symptoms, quality of life, and healthcare costs of the treatment.
Interested in participating?
Request Info16 year and older
All sexes
Interventional
Not applicable
Lentis, Groningen, Provincie Groningen, Netherlands
Study design: Single-blind randomized controlled intervention trial (RCT) with two arms: VR-VOICES as intervention and treatment as usual (TAU) as a control condition.
Study population: Patients with a DSM-5 diagnosis who have experienced distressing AVH for at least 3 months, who are 16 years or older (N=112).
Intervention:
Main study parameters/endpoints: Assessments will be obtained at baseline, within some VR-VOICES sessions, posttreatment (12 weeks after baseline), and at 6-month follow-up. Primary outcome: severity of AVH (total score on the auditory hallucinations scale of the PSYRATS) at post-treatment. Secondary outcomes: in-depth characteristics of AVH such as the frequency, voice impact, beliefs about voices, power relative to voices, levels of anxiety, distress and impact on daily life as measured with questionnaires and diary assessments in the flow of daily life. Other secondary outcomes include clinical symptoms, cost-effectiveness and quality of life.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
7-10 individual VR assisted therapy for voice-hearing session and two booster sessions, in addition to TAU.
Treatment as usual as provided by the mental health centers
Time frame: Between baseline and posttreatment after 3 months
The Psychotic Symptoms Rating Scales (PSYRATS) is a semi-structured interview to assess characteristics of hallucinations and delusions. The auditory hallucinations subscale (AHS), which is used as the primary outcome, has 11 items.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
The Psychotic Symptoms Rating Scales (PSYRATS) is a semi-structured interview to assess characteristics of hallucinations and delusions. The auditory hallucinations subscale (AHS) has 11 items.The delusions subscale (DS) has six items.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
The BAVQ-R has 54 items, measured on a four-point scale: "disagree" (0), "unsure" (1), "slightly agree" (2), "strongly agree"(3).
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
The SCRS has 11 items measuring characteristics of the participants as compared to their voices on a 10-point likert scale ranging from 1-10.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
The VIS has 24 items measured on a 10-point likert scale ranging from 1 (totally disagree) to 10 (totally agree).
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Section A of the VAAS has 12 items and section B 27. Items are rated on a 5-point scale: strongly disagree, disagree, unsure or neutral, or strongly agree.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
The IDS-SR is a 30-item questionnaire. Each item has four statements that reflect various degrees of symptom severity, scored on a four-point scale from 0 to 3.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
The R-GPTS part A consists of 8 items, and B of 10 items. Items are rated on a 5-point scale ranging from 0 (not at all) to 4 (totally).
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
The SERS has 20 items which are rated on a 7-point likert scale from 1 (strongly disagree) -7 (strongly agree).
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
The TiC-P is a self-report questionnaire that consists of two parts. The first part includes 38 structured questions, starting with yes/no questions and followed by a question on the volume of medical consumption.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
The TiC-P is a self-report questionnaire that consists of two parts. The second part deals with 12 questions about work to collect data on productivity losses due to health problems.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life on a scale from 0-10, and assess how many days someone missed work/school/responsibilities and how many days someone was unproductive.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
The first 25 items of this questionnaires are based on five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The patient is asked to indicate their health status by choosing the most appropriate level: no problems, slight problems, moderate problems, severe problems, and extreme problems. The last question indicates their current health status on a scale from 0 to 100.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
The MHCS has 16 items that are measured on a 6-point likert scale ranging from totally not confidant
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
ESM of auditory verbal hallucinations and mental states measured in the flow of daily life. ESM is a structured diary method for reporting momentary experiences 18. Individuals complete short questionnaires on their mobile device, by pressing a link in a text message. Participants will complete ESM 5x daily for 7 days, completion takes ±1 minute. Participants have to complete the questionnaire within 30 minutes after the text message notification, the interval between measurements is 3 hours.
Time frame: Assessment at baseline
21 items on traumatic events, whether they happened, more than once and at which age.
Time frame: Assessment at baseline
10 items to screen trauma which can be answered with yes or no.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Use of prescribed medication in the past 3 months, type of medication, were the medication is for, how often it was used and what amount (in milligram)
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Use of substances, number of glasses of alcohol in the past month. Use of softdrugs and harddrugs in the past 3 months, type of drugs, how often the drugs were used, how much was used each time.
Time frame: Assessment at baseline, 3 months (posttreatment), 6 months (follow-up)
Frequency of use of 21 types of psychological interventions and training in the past 30 days. There is also an option 'other', where specific other interventions and the frequency can be noted down.
Time frame: Assessment at the end of VR-VOICES session 7 (only for the VR-VOICES group), which will be between 7and 10 weeks after baseline is completed.
The WAV has 36 items for the participant and 36 items for the therapist. Items are rated on a 5-point scale ranging from ''never'' to ''always''
Time frame: Assessment during VR-VOICES session 3 & 7 (only for the VR-VOICES group), , which will be between 3-7 weeks (for session 3) and 7-10 weeks (for session 7) after baseline is completed.
The IPQ has 14 items rated on 7-point likert scale ranging from fully disagree to fully agree.
Time frame: Assessment during VR-VOICES session 7 (only for the VR-VOICES group), which will be between 7and 10 weeks after baseline is completed.
Experience of fit of the voice and avatar to the actual voice (two single items on a scale from 1-100).
Time frame: Assessment during each VR-VOICES therapy session (only VR-VOICES group), between baseline and 3 months (follow-up)
Frequency and duration of use of the session recordings by the participant, duration, protocol deviations
Time frame: The interview takes place at 6 months (follow-up) and concerns the experience of the therapy
After the VR-VOICES intervention, in-depth interviews will be performed to collect the experiences of patients with VR-VOICES. This will be done in a subsample of participants (n=20)
Contact information is provided by the study sponsor or research team.
University Medical Center Groningen
Other
Acronym: VR-VOICES
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06599372
Hallucinations, Hallucinations, Verbal Auditory
Neuilly-sur-Marne, France
View Trial DetailsNCT02722915
Hallucinations, Hallucinations, Verbal Auditory
Aachen, Germany
View Trial DetailsNCT06159673
Alzheimer's Disease Psychosis, Behavior
Chandler, Arizona, United States
View Trial DetailsNCT06887192
Alzheimer Disease, Behavior
Phoenix, Arizona, United States
View Trial Details